Combination treatment with valsartan and amlodipine intensifies evening suppression of Bmal1 clock gene in kidneys of spontaneously hypertensive rats

[1] Asmar R, Gosse P, Quere S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Blood Press Monit. 2011;16(2):80-86.10.1097/MBP.0b013e328344c6db21372694Search in Google Scholar

[2] Braun MC, Herring SM, Gokul N et al. Hypertensive renal disease: susceptibility and resistance in inbred hypertensive rat lines. J Hypertens. 2013;31(10):2050-2059.10.1097/HJH.0b013e328362f9a5413035024107734Search in Google Scholar

[3] Cui H, Kohsaka A, Waki H, Bhuiyan ME, Gouraud SS, Maeda M. Metabolic cycles are linked to the cardiovascular diurnal rhythm in rats with essential hypertension. PLoS One. 2011;6(2):e17339.10.1371/journal.pone.0017339304310221364960Search in Google Scholar

[4] Hermida RC, Ayala DE, Fontao MJ, Mojon A, Fernandez JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Int. 2010;27(6):1287-1303.10.3109/07420528.2010.48916720653455Search in Google Scholar

[5] Hermida RC, Calvo C, Ayala DE et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003;42(3):283-290.10.1161/01.HYP.0000084855.32823.DA12874091Search in Google Scholar

[6] Klimas J, Olvedy M, Ochodnicka-Mackovicova K et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19(8):1965-1974.10.1111/jcmm.12573454904725766467Search in Google Scholar

[7] Liu Y, Ushijima K, Ohmori M et al. Chronopharmacology of angiotensin II-receptor blockers in stroke-prone spontaneously hypertensive rats. J Pharmacol Sci. 2011;115(2):196-204.10.1254/jphs.10284FP21282930Search in Google Scholar

[8] Naito Y, Tsujino T, Kawasaki D et al. Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens. 2003;21(6):1107-1115.10.1097/00004872-200306000-0001012777947Search in Google Scholar

[9] Potucek P, Klimas J. Chronotherapy of hypertension with combination treatment. Pharmazie. 2013;68(12):921-925.Search in Google Scholar

[10] Radik M, Doka G, Malikova E, Krenek P, Klimas J. Voluntary exercise and testosterone therapy caused increase in percentage of Myh6 and expression of oxidative stress marker Cybb in left ventricles of rats. Eur Pharm J. 2016;63(1):12-15.10.1515/afpuc-2016-0007Search in Google Scholar

[11] Richards J, Diaz AN, Gumz ML. Clock genes in hypertension: novel insights from rodent models. Blood Press Monit. 2014;19(5):249-254.10.1097/MBP.0000000000000060415942725025868Search in Google Scholar

[12] Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008;9(10):764-775.10.1038/nrg2430375847318802415Search in Google Scholar

[13] Ulu N, Mulder GM, Vavrinec P et al. Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J Pharmacol Exp Ther. 2013;345(3):393-403.10.1124/jpet.113.20349723528611Search in Google Scholar

[14] Vavrinec P, Henning RH, Goris M, Landheer SW, Buikema H, van Dokkum RP. Renal myogenic constriction protects the kidney from age-related hypertensive renal damage in the Fawn-Hooded rat. J Hypertens. 2013;31(8):1637-1645.10.1097/HJH.0b013e328361d50623811996Search in Google Scholar

[15] Vavrinec P, van Dokkum RP, Goris M, Buikema H, Henning RH. Losartan protects mesenteric arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst. 2011;12(3):184-194.10.1177/147032031039132821393360Search in Google Scholar

[16] Woon PY, Kaisaki PJ, Braganca J et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci USA. 2007;104(36):14412-14417.10.1073/pnas.0703247104195881817728404Search in Google Scholar